

**Research Ethics Board
Annual Review/Termination Form**

<p>Received Date</p> <p>REB Use Only</p>
--

Do Not Email, Submit typed, hard copy of this form with “**Original Signature**” for review to the REB office: **OPG Building, 700 University Ave, Suite 8-600, Tor, ON, M5G 1Z5, Phone: (416) 586-4875.**

*(Use the "Tab" key to move between fields)(While cursor is in a field, use the **F1** button for help)*

Principal Investigator (MSH):	MSH REB Number:
Expiry Date of REB Approval: (DD/MMM/YYYY)	Funding Source: <input type="checkbox"/> Current <input type="checkbox"/> Revised, If revised, please provide new funding source information:
Study Title:	
Review type requested: <input type="checkbox"/> Delegated <input type="checkbox"/> Full Board (submit 15 copies) If Full Board is requested, please explain:	
Name Of Person Completing Form:	Contact Email &Telephone #:

STUDY ENROLMENT STATUS

<input type="checkbox"/> NOT STARTED AT MSH	Reason:
For multicentre studies, have any participants been enrolled at other centres?	PLEASE INDICATE ONE: <input type="checkbox"/> Close REB file <input type="checkbox"/> Keep REB file Open
<input type="checkbox"/> ENROLLING SUBJECTS AT MSH	Projected Date of Enrolment Completion: (DD/MMM/YYYY)
<input type="checkbox"/> ENROLLMENT COMPLETE BUT STUDY IS STILL ONGOING: (Check all that applies below) <input type="checkbox"/> Subjects Receiving Study intervention <input type="checkbox"/> Post-Intervention Follow-Up of Subjects (i.e., follow-up visits, data collection only) <input type="checkbox"/> Intervention & Follow-Up Complete For All MSH Subjects - Data Clarification and/or Data Transfer Outside of MSH (i.e., sponsors or coordinating centres)	
Enrolment Termination Date: (DD/MMM/YYYY)	Duration of Follow-Up Period:
<input type="checkbox"/> PREMATURE TERMINATION OF THE STUDY BY INVESTIGATOR OR SPONSOR	
Termination Date: (DD/MMM/YYYY)	Number Enrolled at MSH :
Reason for Termination:	PLEASE INDICATE ONE: <input type="checkbox"/> Close REB file <input type="checkbox"/> Keep REB file open
<input type="checkbox"/> STUDY COMPLETED (i.e., no further patient involvement/data collection, clarification & transfer outside of MSH)	
Date Closed: (DD/MMM/YYYY)	Total Enrollment at MSH :
<<<<<<< Attach a copy of a final report, if available >>>>>>>	PLEASE INDICATE: <input type="checkbox"/> Close REB file

SUMMARY OF SUBJECTS AT MSH ONLY

(Complete as applicable)

Retrospective Chart Review and Tissue Studies N/A

Number of charts reviewed to determine eligibility
Number of participants included in retrospective chart review study
Number of tissue samples utilized during the study

Prospective Studies N/A

Number of charts reviewed for recruitment purposes to determine eligibility
Total number of participants approved by the MSH REB to be enrolled
Number of participants consented
Note: Each participant should be entered below only once so that the sum of the numbers below should be equal to the number of participants consented.
Number of participants consented but did not meet inclusion criteria
Number of participants consented but have not yet started the study procedures
Number of participants who have withdrawn their consent from participation
Number of participants receiving study intervention (e.g. study drug, questionnaires, tests, or procedures done for study purposes)
Number of participants in post-intervention follow-up
Number of participants that have completed the study (including completed follow up and/or withdrawn by PI) and no further contact for study purposes is planned

STUDY SUMMARY

1. PLEASE PROVIDE A BRIEF SUMMARY OF THE PROGRESS OF THE STUDY TO DATE (i.e., recruitment issues, preliminary findings, site staff changes)
2. IS THERE ANY NEW INFORMATION IN THE LITERATURE OR FROM OTHER RECENT STUDIES THAT WOULD CHANGE THE RATIONALE OR RISK/BENEFIT RATIO FOR THIS STUDY (e.g., changes in standard of care, new information about side effects, approval of another drug for this indication, etc)?
 No
 Yes
Describe:
3. HAVE ANY PATIENTS BEEN WITHDRAWN FROM THE STUDY PREMATURELY OR WITHDRAWN CONSENT?
 No
 Yes
Describe:

4. HAVE THERE BEEN ANY SUBJECT COMPLAINTS OR FEEDBACK ABOUT THE RESEARCH? IF YES, PLEASE DESCRIBE.

No

Yes

Describe:

5. BRIEFLY, SUMMARIZE ALL SERIOUS ADVERSE EVENTS (SAEs) THAT HAVE OCCURRED AT MSH ONLY SINCE THE LAST APPROVAL, ACTION TAKEN IN RESPONSE TO THE SAEs, AND ANY RESULTING CHANGES IN PROCEDURES TO DETECT SUCH SAEs.

6. HAS THERE BEEN A CHANGE IN THE FREQUENCY AND/OR SEVERITY OF ADVERSE EVENTS THAT WOULD RESULT IN A CHANGE TO THE PROTOCOL OR CONSENT FORM?

No

Yes

If an amendment has not been submitted, please complete and attach an Amendment Form.

7. IF APPLICABLE, HAS THERE BEEN ANY REPORT FROM THE DATA SAFETY MONITORING COMMITTEE? PLEASE INCLUDE THE MOST RECENT REPORT.

No DSMB

No

Yes

If not yet submitted, please include the most recent report(s).

8. HAS THE STUDY NOW CHANGED TO INCLUDE COLLECTION OR BANKING OF TISSUE OR OTHER SPECIMENS (i.e., fetal tissue, placenta, blood, other body fluids)?

No

Yes

If an amendment has not been submitted, please complete and attach an Amendment Form.

9. SINCE THE LAST RENEWAL, HAS THERE BEEN ANY CHANGE IN THE CONFLICT OF INTEREST INFORMATION PROVIDED TO THE REB FOR INVESTIGATORS INVOLVED IN THIS STUDY? (Potential Conflicts of Interest can include functioning as an employee or consultant to the study sponsor, direct or indirect financial interest in the drug/device or technology involved in the study or receiving honorarium or other benefits from the sponsor.)

No

Yes

Describe:

10. IS THE CONTACT INFORMATION ON THE CONSENT FORM CURRENT?

YES, CURRENT CONSENT FORM(S) ATTACHED

NO, REVISED CONSENT FORM(S) ATTACHED

N/A, NO CONSENT FORM(S) APPROVED FOR THIS STUDY

11. PLEASE PROVIDE A CONTACT NAME, ADDRESS, TELEPHONE NUMBER AND E-MAIL ADDRESS OF THE INDIVIDUAL TO WHOM WE SHOULD SEND STUDY CORRESPONDENCE.

**NEW HEALTH RECORDS CHART RETENTION POLICY FOR STUDY SUBJECTS
EFFECTIVE JULY 13th, 2005**

For studies that require Health Canada approval, the research subject hospital chart must be kept for 25 years. To ensure that Health Records flags the hospital chart for retention for this time period, please advise them of the MRN by completing the information at the following website: <http://info/healthrecords/REBCharts/Form.asp>

Reminder:

Attach a copy of the consent form(s) currently being used and

Retain a copy of the signed form for your records.

PRINCIPAL INVESTIGATOR'S SIGNATURE

I confirm that I have reviewed any adverse events, if applicable, in a timely fashion during the course of the study and these have been reported to the REB. All revisions to the study protocol and consent form have been submitted. I am not aware of any new information that may affect the continuation of the study or require change in the study protocol.

Print Name

Signature

Date (DD/MMM/YYYY)

Reminder:

All changes to the study protocol, consent form(s) and all other study related documents must be submitted for REB review and approval prior to implementation.